FAMOPSIN 20mg Film-coated tablet Ref.[28193] Active ingredients: Famotidine

Source: Υπουργείο Υγείας (CY)  Revision Year: 2018  Publisher: Remedica Ltd, Aharnon Str., Limassol Industrial Estate, 3056 Limassol, Cyprus

4.3. Contraindications

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
  • Patients with a history of hypersensitivity to other H2-receptor antagonists.

4.4. Special warnings and precautions for use

Gastric neoplasm

Gastric malignancy should be excluded prior to initiation of therapy of gastric ulcer with famotidine. Symptomatic response of gastric ulcer to famotidine therapy does not preclude the presence of gastric malignancy.

Renal impairments

Since famotidine is excreted primarily by the kidney, caution should be observed in patients with impaired renal function. A reduction in daily dosage should be considered if creatinine clearance falls below 30 ml/min (see section 4.2).

General

In case of long-term treatment with high dosage, monitoring of blood count and liver function is recommended.

In case of long-standing ulcer disease, abrupt withdrawal after symptom relief should be avoided.

In patients with duodenal and benign gastric ulcers the H. pylori-status should be determined. For H. pylori-positive patients removal of the bacterium H. pylori by means of eradication therapy should be striven for whenever possible.

Elderly

When famotidine was administered to elderly patients in clinical trials, no increase in the incidence or change in the type of drug-related side effects was observed. No dosage adjustment is required based on age alone.

This medicinal product contains lactose and therefore should not be used by patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

4.5. Interaction with other medicinal products and other forms of interaction

No drug interactions of clinical importance have been identified.

Famotidine does not interact with the cytochrome P450-linked drug metabolizing enzyme system. Compounds metabolized by this system which have been tested in man have included warfarin, theophylline, phenytoin, diazepam, propranolol, aminopyrine and antipyrine. Indocyanine green as an index of hepatic blood flow and/or hepatic drug extraction has been tested and no significant effects have been found.

Studies in patients stabilized on phenprocoumon therapy have shown no pharmacokinetic interaction with famotidine and no effect on the pharmacokinetic or anticoagulant activity of phenprocoumon.

In addition, studies with famotidine have shown no augmentation of expected blood alcohol levels resulting from alcohol ingestion.

Alterations of gastric pH may affect the bioavailability of certain drugs resulting in an altered absorption.

The absorption of ketoconazole and itraconazole could be reduced. Ketoconazole should be given 2 hours before famotidine administration.

Antacids may decrease the absorption of famotidine and lead to lower plasma concentrations of famotidine. Famotidine should therefore be taken 1 – 2 hours before the application of an antacid.

The administration of probenecid can delay the elimination of famotidine.

Concomitant use of probenecid and Famotidine should therefore be avoided.

The concomitant use of sucralfate should be avoided within two hours of the famotidine dose.

If famotidine, atazanavir and ritonavir are co-administered, a dose of 20 mg famotidine should not be exceeded. If a higher dose of famotidine is required (e.g. famotidine 40 mg) dose adjustment of atazanavir and ritonavir may be considered. Co-administration of famotidine, atazanavir, ritonavir and tenofovir should be avoided. If the combination of famotidine, atazanavir, ritonavir and tenofovir is judged unavoidable, close clinical monitoring is recommended.

Risk of loss of efficacy of calcium carbonate when co-administered as phosphate binder with famotidine in haemodialysis patients.

4.6. Pregnancy and lactation

Pregnancy

Famotidine is not recommended for use in pregnancy, and should be prescribed only if clearly needed. Before a decision is made to use famotidine during pregnancy, the physician should weigh the potential benefits from the drug against the possible risks involved.

Breast-feeding

Famotidine is detectable in human milk. Nursing mothers should either stop this drug or stop nursing.

4.7. Effects on ability to drive and use machines

Some patients have experienced adverse reactions such as dizziness and headache while taking famotidine. Patients should be informed that they should avoid driving vehicles or operating machinery or doing activities which require prompt vigilance if they experience these symptoms (see section 4.8).

4.8. Undesirable effects

Tabulated list of adverse reactions

Frequencies are defined as common (≥1/100 to <1/10); uncommon (≥1/1.000 to <1/100); rare (≥1/10.000 to <1/1.000); very rare (<1/10.000), not known (cannot be estimated from the available data).

System Organ ClassCommonUncommonRareVery rare
Blood and
lymphatic
system
disorders
   leukopenia,
thrombocytopenia,
neutropenia,
agranulocytosis,
pancytopenia
Immune system
disorders
   hypersensitivity
reactions
(anaphylaxis,
angioneurotic
oedema,
bronchospasm)
Metabolism and
nutrition
disorders
 anorexia  
Psychiatric
disorders
   reversible psychic
disturbances
including
depression,
anxiety disorders,
agitation,
disorientation,
confusion,
hallucinations,
insomnia
Nervous system
disorders
headache,
dizziness
  convulsions,
grand mal seizures
(particularly in
patients with
impaired renal
function),
paresthesia,
drowsiness,
somnolence
Respiratory,
thoracic and
mediastinal
disorders
   interstitial
pneumonia
sometimes fatal
Gastrointestinal
disorders
constipation,
diarrhoea
dry mouth,
nausea and/or
vomiting,
abdominal
discomfort or
distension,
flatulence,
dysgeusia
  
Hepatobiliary
disorders
   liver enzyme
abnormalities,
hepatitis,
cholestatic
jaundice
Skin and
subcutaneous
tissue disorders
 rash, pruritus,
urticaria
 alopecia,
Stevens-Johnson
syndrome/toxic
epidermal
necrolysis
sometimes fatal
Musculoskeletal
and connective
tissue disorders
  arthralgiamuscle cramps
Reproductive
system and
breast disorders
   Impotence,
reduced libido
General
disorders and
administration
site conditions
 fatigue chest tightness
Investigations   increase in
laboratory
values
(transaminases,
gamma-GT,
alkaline
phosphatase,
bilirubin)
 

Adverse effects – causal relationship unknown

Rare cases of gynaecomastia, have been reported, however, in controlled clinical trials the incidences were not greater than those seen with placebo.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: Cyprus, Pharmaceutical Services, Ministry of Health, CY-1475 Nicosia, Fax: +357 22608649, Website: www.moh.gov.cy/phs.

6.2. Incompatibilities

Not applicable.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.